Human leukocyte antigen A classical class I family consists of three members including HLA-A, HLA-B and HLA-C. Members of classical class I major histocompatibility complex (MHC) contain a peptide bound to a transmembrane glycoprotein subunit, the heavy chain, in association with a soluble light chain called β2-microglobulin. Class I MHC molecules are present in changeable volumes on all nucleated cells.
The antibody W6/32 recognises MHC Class I molecules (MHC Class Ia) that are expressed on the surface of all human nucleated cell types. The antibody W6/32 is a valuable reagent for analysing variations in HLA class I expression in different disease states e.g. liver disease, muscular dystrophy, inflammatory myopathy and other neuromuscular disorders.
The previously assigned protein identifier P01891 has been merged into P04439. Full details can be found on the UniProt database.
Immunogen
Membrane of human tonsil cells
Application
The reagent is designed for Flow Cytometry analysis. Suggested working dilution for Flow Cytometry is 2-8 μg/mL of sample. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
Biochem/physiol Actions
Human leukocyte antigen A class I downregulation is implicated in tumor invasion and development. Genetic variations in the class I major histocompatibility complex (MHC) is associated with the development of melanoma. HLA-viral peptide interaction plays a major role in the regulation of human immunodeficiency virus (HIV) infection.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Solution in azide free phosphate buffered saline, pH 7.4; 0.2 um filter sterilized. Endotoxin level is less than 0.01 EU/ug of the protein, as determined by the LAL test.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
All-trans retinoic acid (ATRA), a recognized differentiating agent, has significant potential in the personalized/stratified treatment of breast cancer. The present study reports on the molecular mechanisms underlying the anti-tumor activity of ATRA in breast cancer. The work is based on
Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids
Salter RD
Immunogenetics, 21, 235-246 (1985)
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.
Garrido F
Immunology Today, 18, 89-95 (1997)
Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevance
Ferrone S and Marincola FM
Immunology Today, 16, 487-494 (1995)
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.